Otsuka reports 12.8% revenue increase in H1 2026
Revenue rose to ¥1.33 trillion, operating profit up 15.0%, and net profit up 24.3%, driven by Rexulti and other key products.
See the latest news and media coverage for Otsuka. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global healthcare holding company
otsuka.comLast updated
In short: Otsuka reported strong financial results and secured several key drug approvals, including FDA clearance for VOYXACT and an ADHD pill.
Revenue rose to ¥1.33 trillion, operating profit up 15.0%, and net profit up 24.3%, driven by Rexulti and other key products.
Sales revenue is 1.332 trillion yen, business profit is 280 billion yen, both strong. The delay in generic entry for Jinarc and Abilify Maintena also contributed.
In collaboration with Enaris and Tes, a storage battery will be installed alongside the solar power generation at the Kushiro plant. It will automatically optimize power supply and demand, maximizing renewable energy use and stabilizing power.
The report introduces mid- to long-term value creation and well-being initiatives, and includes human resource strategy for the first time.
Otsuka Holdings Co. Ltd. (4578.TO) Japan Half-Year Ended June 30 GROUP 2026 2025 Revenue Y1.33 tln Y1.18 tln Operating Profit Y278.54 bln Y242.12 bln Pretax...
Otsuka Holdings Co., Ltd. published its financial results for the half-year ended June 30, 2026. For this period, the company recorded a...
Detailed price information for Otsuka Holdings CO ADR (OTSKY) from The Globe and Mail including charting and trades.
Detailed price information for Otsuka Holdings CO Ltd (OTSKF) from The Globe and Mail including charting and trades.
Track Otsuka and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Otsuka and other trending companies.